THERAPEUTIC FOCUS
RESEARCH & DEVELOPMENT
PUBLICATION
PARTNERING
Shareholder Tools
Briefcase Printed Materials Email Alerts Download Center snapshot RSS

Overview

NASDAQ: AMRN
Price:
1.57
Change:
- 0.03
4:00 PM ET on 17 Apr 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) capsules is Amarin's first FDA approved product and is available in the United States by prescription. Vascepa is the first and only pure EPA omega-3 fatty acid that has been clinically proven to significantly reduce TG levels without increasing LDL-C and providing a spectrum of additional lipid treatment benefits with a tolerability and safety profile similar to placebo. For more information about Vascepa visit www.vascepa.com.

Vascepa® (icosapent ethyl) capsules is a patented, pure EPA omega-3 fatty acid clinically proven to reduce triglycerides without raising LDL-C. In July 2012, Vascepa received FDA approval in the United States for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia and is now available by prescription. The only reported adverse reaction with an incidence >2% and greater than placebo in Vascepa treated patients was arthralgia (2.3% for Vascepa vs. 1.0% for placebo).

See important safety information about Vascepa

See full prescribing information for Vascepa

Amarin is also developing Vascepa for use in the treatment of adult patients with high triglyceride levels (≥200 mg/dL and <500 mg/dL) who are also on statin therapy for elevated LDL-C levels, the population studied in the ANCHOR trial. The FDA has not reviewed the clinical results of the ANCHOR trial. Amarin plans to separately seek FDA approval for use of Vascepa in this patient population after Amarin's REDUCE-IT cardiovascular outcomes trial is substantially underway. Each of the MARINE, ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA.

Amarin is headquartered in Dublin, Ireland. In the U.S., the Company's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

View all »Annual Meeting Materials

27 Feb 2014
Form 10-K
27 Apr 2012
Proxy 2012

View all »   RSSRecent Releases

31 Mar 2014
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules

27 Feb 2014
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations

Company Registrars

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013

Equiniti
PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex, BN99 6QQ

Investor Relations Contacts

Amarin Corporation plc
t: 860 572 4979
e: investor.relations@amarincorp.com